Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.83 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.83 |
| ▸ | CSF1R | P07333 | 15/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909883 | 0.93 | CSF1R (0.76) | KCNH2SCN5ACSF1R | |
| SCHEMBL2912427 | 0.92 | KCNH2 (0.85) | KCNH2SCN5ACSF1R | |
| SCHEMBL2914241 | 0.92 | KCNH2 (0.85) | KCNH2SCN5ACSF1R | |
| SCHEMBL1276312 | 0.91 | KCNH2 (1.00) | KCNH2SCN5ACSF1R | |
| SCHEMBL2912202 | 0.90 | KCNH2 (0.86) | KCNH2SCN5ACSF1R | |
| SCHEMBL2911805 | 0.89 | KCNH2 (0.80) | KCNH2SCN5ACSF1R | |
| SCHEMBL2905011 | 0.89 | KCNH2 (0.80) | KCNH2SCN5ACSF1R | |
| SCHEMBL2913222 | 0.89 | KCNH2 (0.85) | KCNH2SCN5ACSF1R | |
| SCHEMBL2910976 | 0.89 | KCNH2 (0.85) | KCNH2SCN5ACSF1R | |
| SCHEMBL2910242 | 0.88 | KCNH2 (0.84) | KCNH2SCN5ACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | KCNH2 3655/4885SCN5A 2645/4885CSF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.